Summit Therapeutics Inc. Common Stock
SMMTSummit Therapeutics Inc. is a biotechnology company focused on developing innovative medicines for serious and rare diseases. The company specializes in discovering and advancing novel therapies, often leveraging innovative science and technology platforms. Its pipeline includes candidates targeting bacterial infections, genetic disorders, and other critical health conditions.
Company News
Ten large-cap stocks experienced significant declines during the week of January 12-16, 2026. Regencell Bioscience led losses with a 42.08% drop, while Trip.com fell 20.19% following a Chinese anti-monopoly investigation. Other major decliners included Atlassian (19.82%), Figma (19.41%), HubSpot (16.56%), and Intuit (14.38%), with analyst downgra...
Alumis shares surged 94.53% following positive Phase 3 trial results for envudeucitinib, an oral TYK2 inhibitor for psoriasis that met primary and secondary endpoints. The company announced plans to raise $175 million in capital to support commercialization of the drug and its pipeline. The broader market rose modestly with the S&P 500 gaining 0....
Summit Therapeutics, a healthcare company with a $14 billion market cap, is banking on its promising cancer drug ivonescimab, which showed potential superiority to Keytruda in clinical trials. However, the stock remains risky due to ongoing global trials and uncertain FDA approval.
Wall Street analysts highlight three potential comeback stocks across different sectors: The Trade Desk, Summit Therapeutics, and Sprouts Farmers Market, each facing challenges but showing promising signs of recovery.
Summit Therapeutics reported positive Phase 3 trial results for ivonescimab in lung cancer treatment, showing a 40% reduced risk of progression or death compared to competitor therapy, and plans to submit a Biologics License Application in Q4 2025.
